Contineum Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Contineum Therapeutics, Inc. quarterly Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • Contineum Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$10.3M, a 64.2% decline year-over-year.
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$10.3M -$4.02M -64.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$9.01M -$50.6M -122% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$8.42M -$3.59M -74.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q3 2023 -$6.25M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $41.6M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$4.82M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.